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Jingliang Ju*. Shanghai Rendu Biotechnology Co., Ltd, Shanghai,
China
SAT (Simultaneous Ampliﬁcation and Testing) is an isothermal
real-time detection technique allowing rapid ampliﬁcation and
detection of speciﬁc regions of nucleic acid from a diverse range
of sources. It is especially suitable for RNA. A series of SAT
products have been developed allowing the detection of RNAs
from inﬂuenza virus A, inﬂuenza virus B, seasonal inﬂuenza (Hu-
H3N2 and Hu-H1N1), inﬂuenza virus A subtype H1N1, avian ﬂu
H5N1. These SAT-based products are speciﬁc for each type or
subtype of the viruses and do not cross-react with other inﬂuenza
subtypes. The assay is 10- to 100-fold more sensitive than most
of the commercially available real-time PCR system. Combined
with an easy magnetic-based sample processing method, the
SAT assay can be used in high throughput inﬂuenza screening
programmers.
IF-02 Successful Control of Inﬂuenza Using Stockpile of
Tamiﬂu® during 2003/2004 SARS Period
Ih-Jen Su*. Division of Infectious Diseases, National Health
Research Institutes, Tainan, Taiwan
The common clinical manifestations shared by severe respiratory
virus infection (SARS) and inﬂuenza constitute a big challenge
for the successful control of SARS during the winter ﬂu period
2003/2004 in Taiwan. In the belief that the far majority of ﬂu-like
illness (ILI) will actually represent inﬂuenza in the ﬂu season and
to avoid confusion and panic of SARS suspect in the post-SARS
period, the Center for Disease Control of Taiwan implemented
a national policy of ILI control measure which includes public
health measures and the stockpile of antivirals-Tamiﬂu® for the
control of ﬂu-like illness (ILI) in the 2003/2004 winter period,
particularly for the control of institutional outbreak of ILI illness.
The control policy includes the real-time reporting of ILI cluster-
ing in the institutions such as nursing home, school, military, and
jail. Upon receiving the reporting, a task force team was immedi-
ately dispatched to investigate the outbreak. After sampling the
throat swab specimens, anti-virals were given to the patients and
close contacts. The transmission and clinical outcome were then
followed up in the coming weeks. A total of 24 institutional ILI
outbreaks were reported in the 2003/2004 winter period. Among
which, 23.4% of the cases (609 samples taken, 143 positive) were
laboratory-proved to be caused by inﬂuenza by the laboratory
by a combination of ELISA kit for inﬂuenza, PCR for inﬂuenza
and SARS-CoV, and viral culture. None of them were caused by
SARS-CoV. All the ILI outbreaks were successfully controlled by
this measure and no more transmission was reported following
the application of anti-virals. In parallel to this control measure,
the ILI incidence of ILI cases reported by sentinel physician sur-
vey reduced remarkably to 30 cases in 2003/2004 as compared
to the 80 cases at the periods before SARS. Laboratory survey of
30 viral isolates collected between 2004-2007 revealed no drug
resistance to oseltamivir. Therefore, the control policy of ILI
illness by combining public health measures and stockpile of an-
tivirals Tamiﬂu® proves to be effective and successful measures
to control the institutional outbreaks of inﬂuenza. This strategy
can be considered to be applied during the H1N1/H5N1 pandemic
ﬂu.
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Aim: Recently, an extremely high prevalence of oseltamivir-
resistant A/H1N1 virus with mutation H274Y has been reported.
However, the clinical effectiveness of oseltamivir or zanamivir
for A/H1N1 virus with the H274Y mutation has not been ade-
quately evaluated. We evaluated the clinical effectiveness of
oseltamivir or zanamivir for inﬂuenza A/H1N1 virus with H274Y
mutation.
Methods: The patients consisted of 164 A/H1N1 and 59 A/H3N2
patients in the 2008-2009 season and 68 A/H1N1 patients in
the 2007-2008 season. Neuraminidase inhibition assays (IC50) for
oseltamivir and sequence analyses were performed using in-
ﬂuenza viruses isolated from these patients. Body temperature
was evaluated before and on the second, third, and fourth days
after starting treatment. The duration of fever (temperature, ≥
37.5°C) after the ﬁrst dose of oseltamivir or zanamivir and from
onset was measured. Inﬂuenza virus was isolated and its subtype
and the H274Y neuraminidase mutation status were determined.
Results: All of the 49 A/H1N1 virus isolates analyzed in the
2008-2009 season but none from the 2007-2008 season contained
the H274Y mutation. The mean IC50 before oseltamivir treatment
was signiﬁcantly higher in 2008-2009 (319.3 ± 185.4 nM) than
in 2007-2008 (1.5 ± 0.8 nM; p<0.001). The reisolation rate of
A/H1N1 virus was signiﬁcantly higher in the age group of ≤ 15
years (50.0%) than > 15 years (11.8%) in the 2008-2009 season
(p=0.038). Body temperature was signiﬁcantly higher on the third
and fourth days after starting treatment in the 2008-2009 season
than in the 2007-2008 season in patients ≤ 15 years. The duration
of fever after the start of oseltamivir therapy was signiﬁcantly
longer in A/H1N1 patients (49.1±30.2 h) than in A/H3N2 patients
(33.7±20.1 h, p<0.01) in the 2008-2009 season or the 2007-2008
A/H1N1 patients (32.0±18.9 h, p<0.001). The duration of fever
after the ﬁrst dose of oseltamivir was signiﬁcantly longer than
that with zanamivir in the 2008-2009 A/H1N1 patients (p<0.001).
The duration of fever from onset for the A/H1N1 patients was
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